Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
The Pharma Letter9d
Biocon and Civica link up on Insulin Aspart access in USA
Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...
GlobalData on MSN10d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025
Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...
Medical Dialogues9d
Biocon Biologics, Civica join hands to expand Insulin Aspart access in US
Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...
Yahoo Finance9d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...
The Victoria Advocate10d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan.It has a pipeline of 12 biosimilar assets under ...
Medical Dialogues8d
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...